Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers:: A cautionary tale

被引:5
作者
Antill, Yoland C.
Mitchell, Gillian
Johnson, Sandra A.
Devereux, Lisa
Milner, Alvin
Phillips, Kelly-Anne
Campbell, Ian G.
机构
[1] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic 8006, Australia
[2] Peter MacCallum Canc Ctr, Victorian Breast Canc Res Consortium Canc Genet L, Div Res, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
关键词
D O I
10.1158/1055-9965.EPI-05-0986
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Loss of heterozygosity (LOH) in breast ductal lavage (DL) fluid has been reported to be a potential biomarker of malignant change. Interpretation of LOH is reliant on sufficient quality and quantity of DNA. We investigated LOH of the BRCA1/2 loci in DL samples from BRCA1/2 mutation carriers, while also assessing the effect of DNA quantity. Methods: DNA yield was estimated using quantitative realtime PCR. Allelic status of DL DNA was determined using fluorescently tagged microsatellite markers with the subject's lymphocytic DNA serving as a control. Samples were scored as consistently heterozygous or as demonstrating LOH if the same result was observed in replicate experiments. Additionally, samples were scored as "discordant LOH" if they initially showed LOH, but in replicate experiments either showed heterozygosity or LOH of the opposite allele. Results: In 11 BRCA1 carriers, 46 ducts were assessable, and 39 ducts from 14 BRCA2 carriers were assessable. LOH was observed in 17% and 18% of ducts from BRCA1 and BRCA2, respectively. Discordant results were seen in 23 BRCA1 (50%) and 15 BRCA2 (38%) samples. DNA yield was significantly greater in samples that were consistently heterozygous than those that were either discordant or showed LOH in replicate experiments for both BRCAI (P = 0.003) and BRCA2 (P = 0.003). Conclusions: DNA quantity is highly variable between DL samples, with low yields likely to detrimentally affect the interpretation of LOH. In conclusion, LOH may not be an adequate method to detect the early stages of malignant change in samples obtained via DL.
引用
收藏
页码:1396 / 1398
页数:3
相关论文
共 15 条
[1]
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[2]
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk [J].
Brekelmans, CTM ;
Seynaeve, C ;
Bartels, CCM ;
Tilanus-Linthorst, MMA ;
Meijers-Heijboer, EJ ;
Crepin, CMG ;
van Geel, AN ;
Menke, M ;
Verhoog, LC ;
van den Ouweland, A ;
Obdeijn, IM ;
Klijn, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :924-930
[3]
Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[4]
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer [J].
Dooley, WC ;
Ljung, BM ;
Veronesi, U ;
Cazzaniga, M ;
Elledge, RM ;
O'Shaughnessy, JA ;
Kuerer, HM ;
Hung, DT ;
Khan, SA ;
Phillips, RF ;
Ganz, PA ;
Euhus, DM ;
Esserman, LJ ;
Haffty, BG ;
King, BL ;
Kelley, MC ;
Anderson, MM ;
Schmit, PJ ;
Clark, RR ;
Kass, FC ;
Anderson, BO ;
Troyan, SL ;
Arias, RD ;
Quiring, JN ;
Love, SM ;
Page, DL ;
King, EB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (21) :1624-1632
[5]
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors [J].
Esteller, M ;
Silva, JM ;
Dominguez, G ;
Bonilla, F ;
Matias-Guiu, X ;
Lerma, E ;
Bussaglia, E ;
Prat, J ;
Harkes, IC ;
Repasky, EA ;
Gabrielson, E ;
Schutte, M ;
Baylin, SB ;
Herman, JG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) :564-569
[6]
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR [J].
Evron, E ;
Dooley, WC ;
Umbricht, CB ;
Rosenthal, D ;
Sacchi, N ;
Gabrielson, E ;
Soito, AB ;
Hung, DT ;
Ljung, BM ;
Davidson, NE ;
Sukumar, S .
LANCET, 2001, 357 (9265) :1335-1336
[7]
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer [J].
Fackler, MJ ;
McVeigh, M ;
Mehrotra, J ;
Blum, MA ;
Lange, J ;
Lapides, A ;
Garrett, E ;
Argani, P ;
Sukumar, S .
CANCER RESEARCH, 2004, 64 (13) :4442-4452
[8]
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[9]
Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from high-risk patients [J].
Isaacs, C ;
Cavalli, LR ;
Cohen, Y ;
Pennanen, M ;
Shankar, LK ;
Freedman, M ;
Singh, B ;
Liu, M ;
Gallagher, A ;
Rone, JD ;
Dickson, RB ;
Sidransky, D ;
Haddad, BR .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 84 (02) :99-105
[10]
Immunocytochemical analysis of breast cells obtained by ductal lavage [J].
King, BL ;
Crisi, GM ;
Tsai, SC ;
Haffty, BG ;
Phillips, RF ;
Rimm, DL .
CANCER CYTOPATHOLOGY, 2002, 96 (04) :244-249